Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral milciclib in previously treated malignant thymoma or thymic carcinoma
2013-000344-25Phase 2Terminated
- Sponsor
- Nerviano Medical Sciences
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of milciclib in thymoma and thymic carcinoma (TC), sponsored by Nerviano Medical Sciences. Primary endpoint: Progression-free survival rate at 3 months. Started Feb 2013; status: terminated.
02
Drugs
milciclib
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on 2013-000344-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000344-25.